{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:03:24Z","timestamp":1780401804898,"version":"3.54.1"},"reference-count":24,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Rhabdomyosarcoma (RMS) confined to the bone marrow represents an exceptionally rare and aggressive presentation that can mimic primary hematological malignancies, often leading to diagnostic delays and therapeutic challenges. We report the case of a 34-year-old woman who presented with clinical and laboratory findings highly suggestive of a hematological disorder, including cytopenias and diffuse bone marrow involvement. Initial evaluation raised suspicion for leukemia; however, comprehensive diagnostic work-up, including immunohistochemistry and molecular studies, ultimately confirmed the diagnosis of PAX3\/FOXO1 gene-rearranged alveolar RMS isolated in the bone marrow, with no identifiable primary soft tissue mass. The patient was treated with an intensive multi-agent chemotherapy regimen, resulting in a marked hematological recovery and a significant radiological improvement after a limited number of cycles. We further reviewed the limited literature on bone-marrow-confined RMS, highlighting the proposed pathophysiological mechanisms, diagnostic pitfalls, and reported treatment strategies. Given the absence of standardized management guidelines for this rare entity, therapeutic approaches are often extrapolated from conventional RMS protocols or regimens used for high-grade sarcomas. Our experience supports the potential efficacy of intensive chemotherapy in achieving meaningful clinical responses. This case report emphasizes the challenges in the diagnosis of RMS confined to the bone marrow due to its atypical presentation. It also highlights the poor prognosis and aggressiveness of this entity compared to conventional RMS.<\/jats:p>","DOI":"10.3390\/curroncol33060331","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:14:57Z","timestamp":1780395297000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rhabdomyosarcoma Confined to the Bone Marrow: A Case Report and Literature Review"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-3828","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Hodroj","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Batrouni","sequence":"additional","affiliation":[{"name":"Medical Research Volunteer Program (MRVP), American University of Beirut, Beirut 1107-2020, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre da Silva","family":"Faco Junior","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-4224","authenticated-orcid":false,"given":"Mohammad Amin","family":"Salehi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-9316","authenticated-orcid":false,"given":"Ramy","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zarrabi, A., Perrin, D., Kavoosi, M., Sommer, M., Sezen, S., Mehrbod, P., Bhushan, B., Machaj, F., Rosik, J., and Kawalec, P. (2023). Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies. Cancers, 15.","DOI":"10.20944\/preprints202309.0846.v1"},{"key":"ref_2","unstructured":"Kaseb, H., Kuhn, J., Gasalberti, D.P., and Babiker, H.M. (2026). Rhabdomyosarcoma. StatPearls, StatPearls Publishing LLC."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00428-021-03026-4","article-title":"FOXO1 gene involvement in a non-rhabdomyosarcomatous neoplasm","volume":"479","author":"Haefliger","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1684\/bdc.2014.2017","article-title":"Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway","volume":"101","author":"Orbach","year":"2014","journal-title":"Bull. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/PAS.0000000000000538","article-title":"A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases","volume":"40","author":"Alaggio","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13256-025-05225-y","article-title":"Pleomorphic rhabdomyosarcoma in adults: A case report","volume":"19","author":"Aminparast","year":"2025","journal-title":"J. Med. Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41388-026-03767-z","article-title":"TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma","volume":"45","author":"Vuong","year":"2026","journal-title":"Oncogene"},{"key":"ref_9","first-page":"115","article-title":"Rhabdomyosarcoma in adolescent and young adult patients: Current perspectives","volume":"5","author":"Huh","year":"2014","journal-title":"Adolesc. Health Med. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nakano, K. (2026). The Development of Novel Treatment Strategies for Rhabdomyosarcoma. Cancers, 18.","DOI":"10.3390\/cancers18040690"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/mpo.2950160212","article-title":"Rhabdomyosarcoma presenting with diffuse bone marrow involvement, hypercalcemia and renal failure","volume":"16","author":"Martinez","year":"1988","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e29967","DOI":"10.1002\/pbc.29967","article-title":"Rhabdomyosarcoma with unknown primary tumor site: A report from European pediatric Soft tissue sarcoma Study Group (EpSSG)","volume":"69","author":"Affinita","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-3329-2-12","article-title":"Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing\u2019s and other Small Round Cell Sarcomas","volume":"2","author":"Whelan","year":"2012","journal-title":"Clin. Sarcoma Res."},{"key":"ref_14","first-page":"S38","article-title":"Leukemic masquerade of adult alveolar rhabdomyosarcoma confined to bone marrow: A rare case","volume":"36","author":"Kaur","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ccr3.2284","article-title":"Rhabdomyosarcoma debut masquerading as acute lymphoblastic leukemia: A case report and review of the literature","volume":"7","author":"Duran","year":"2019","journal-title":"Clin. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13569-015-0039-6","article-title":"Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET\/CT","volume":"5","author":"Karagiannis","year":"2015","journal-title":"Clin. Sarcoma Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1066896914553666","article-title":"A leukemic presentation of alveolar rhabdomyosarcoma in a 52-year-old woman without an identifiable primary tumor","volume":"23","author":"Kern","year":"2015","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.1148","article-title":"Hematologic masquerade of rhabdomyosarcoma","volume":"68","author":"Sandberg","year":"2001","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00043426-199608000-00015","article-title":"Rhabdomyosarcoma presenting as acute leukemia","volume":"18","author":"Morandi","year":"1996","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pbc.21093","article-title":"Comparison of results of a pilot study of alternating vincristine\/doxorubicin\/cyclophosphamide and etoposide\/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: A report from the Children\u2019s Oncology Group","volume":"50","author":"Arndt","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10585-007-9094-6","article-title":"The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma","volume":"25","author":"Strahm","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2217\/fon.13.193","article-title":"CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis","volume":"10","author":"Shi","year":"2014","journal-title":"Future Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2045-3329-2-24","article-title":"The CXCR4-CXCL12 axis in Ewing sarcoma: Promotion of tumor growth rather than metastatic disease","volume":"2","author":"Berghuis","year":"2012","journal-title":"Clin. Sarcoma Res."},{"key":"ref_24","first-page":"651","article-title":"FDG-PET\/CT is superior to bone scan for detection of bone metastases from rhabdomyosarcoma at staging","volume":"55","author":"Fox","year":"2014","journal-title":"J. Nucl. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:13:35Z","timestamp":1780398815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060331"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060331","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}